Early adverse drug event signal detection within population-based health networks using sequential methods: Key methodologic considerations

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 3, 2009, Pages 226-234

  Brown, Jeffrey S ^a,b   Kulldorff, Martin ^a   Petronis, Kenneth R ^c   Reynolds, Robert ^c   Chan, K Arnold ^d,e   Davis, Robert L ^f   Graham, David ^g   Andrade, Susan E ^b,h   Raebel, Marsha A ^b,f   Herrinton, Lisa ^b,f   Roblin, Douglas ^b,f   Boudreau, Denise ^b,i   Smith, David ^b,f   Gurwitz, Jerry H ^b,h   Gunter, Margaret J ^b,j   Platt, Richard ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HMO Research Network Center for Education and Research in Therapeutics   (United States)

^c PFIZER INC   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e i3 Drug Safety   (United States)

^f KAISER PERMANENTE   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ CENTER FOR HEALTH STUDIES   (United States)

^j LOVELACE CLINIC FOUNDATION   (United States)

more..

Author keywords

Adverse drug event; MaxSPRT; Methodology; Safety surveillance; Sequential analysis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CELECOXIB; CERIVASTATIN; CETIRIZINE; CLEMASTINE; DICLOFENAC; FEXOFENADINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LORATADINE; NAPROXEN; ROFECOXIB; VALDECOXIB; DRUG;

ACUTE HEART INFARCTION; ANALYTIC METHOD; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; INCIDENCE; MAXIMAZED SEQUENTIAL PROBABILITY RATIO TEST; MAXIMUM LIKELIHOOD METHOD; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RHABDOMYOLYSIS; SIGNAL DETECTION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HEALTH SURVEY; INSURANCE; MEDICAL RECORD; METHODOLOGY; ORGANIZATION AND MANAGEMENT; POSTMARKETING SURVEILLANCE; STATISTICS; TIME; TREATMENT OUTCOME; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMPETITIVE MEDICAL PLANS; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INSURANCE CLAIM REVIEW; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; PHARMACEUTICAL PREPARATIONS; POPULATION SURVEILLANCE; PRODUCT SURVEILLANCE, POSTMARKETING; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 65249168893     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1706     Document Type: Article

References (30)

1. Piazza-Hepp TD, Kennedy DL. Reporting of adverse events to Med-Watch. Am J Health Syst Pharm 1995; 52(13): 1436-1439.
2. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005 165(12): 1363-1369.
3. Alina Baciu KS, Sheila P B (eds). The Future of Drug Safety: Promoting and Protecting the Health of the Public. Institute of Medicine of the National Academies: Washington, D.C., 2006; Committee on the Assessment of the US Drug Safety System.
4. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281(9): 824-829.
5. McClellan M. Drug safety reform at the FDA-pendulum swing or systematic improvement? N Engl J Med. 2007; 356(17): 1700-1702.
6. U.S. Food and Drug Administration. Law Strengthens FDA. http://www.fda.gov/oc/initiatives/advance/fdaaa.html. [Accessed 6 Feb 2008].
7. Hennessy S, Strom BL. PDUFA reauthorization-drug safety's golden moment of opportunity? N Engl J Med. 2007; 356(17): 1703-1704.
8. Psaty BM, Burke SP. Protecting the health of the public-Institute of Medicine recommendations on drug safety. N Engl J Med. 2006; 355(17): 1753-1755.
9. Psaty BM, Charo RA. FDA responds to institute of medicine drug safety recommendations-in part. JAMA 2007; 297(17): 1917-1920.
10. Psaty BM, Korn D. Congress responds to the IOM drug safety report-in full. JAMA 2007; 298(18): 2185-2187.
11. U.S., Food and Drug Administration. The Sentinel Initiative: National Strategy for Monitoring Medical Product Safety. http://www.fda.gov/oc/ initiatives/advance/reports/report0508.html
12. Brown JS, Kulldorff M, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf. 2007; 16(12): 1275-1284.
13. Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology 2005; 16(3): 336-341.
14. Lieu TA, Kulldorff M, Davis RL, et al. Real-Time vaccine safety surveillance for the early detection of adverse events. Med Care 2007; 45(10): S89-S95.
15. Clark JA, Klincewicz SL, Stang PE. Spontaneous adverse event signaling methods: classification and use with health care treatment products. Epidemiol Rev. 2001; 23(2): 191-210.
16. Platt R, Davis R, Finkelstein J, et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf. 2001; 10(5): 373-377.
17. Merck & Company. Prinivil (Lisinopril) product label. http://www.merck.com/product/usa/pi_circulars/p/prinivil/ prinivil_pi.pdf. [Accessed 30 April 2008]
18. U.S. Food and Drug Administration. Baycol information. http://www.fda.gov/cder/drug/infopage/baycol/default.htm. [Accessed 30 April 2008]
19. U.S. Food and Drug Administration. Safety of Vioxx. FDA Public Health Advisory http://www.fda.gov/cder/drug/infopage/vioxx/PHA_vioxx.htm. [Accessed 30 April 2008]
20. U.S. Food and Drug Administration. FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). FDA Public Health Advisory http://www.fda.gov/cder/drug/advisory/COX2.htm. [Accessed 30 April 2008]
21. McMahon AD, Evans JM, McGilchrist MM, McDevitt DG, MacDonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 1998; 7(4): 275-280.
22. van Staa TP, Abenhaim L, Leufkens H. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. J Clin Epidemiol 1994; 47(2): 183-189.
23. Kulldorff M. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Presented at: Vaccine Safety Datalink Annual Meeting, 2006; Berkeley, CA.
24. Kulldorff M, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Working Paper. 2008; available at www.dacp.org/faculty_kulldorff. html
25. Center for Disease Control and Prevention. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. 2008; 57(10): 258-260.
26. Lieu T. Rapid cycle analysis for early detection of vaccine adverse events. Presented at: Advisory Committee on Immunization Practices 27 February 2008; Atlanta, GA.
27. Klein N. Vaccine Safety Datalink project: Evaluation of MMRV and febrile seizures. Presented at: Advisory Committee on Immunization Practices 27 February 2008.
28. Spiegelhalter D, Grigg O, Kinsman R, Treasure T. Risk-adjusted sequential probability ratio tests: applications to Bristol, Shipman and adult cardiac surgery. Int J Qual Health Care 2003; 15(1): 7-13.
29. Wald A. Sequential tests of statistical hypotheses. Ann Math Stat 1945; 16: 177-186.
30. Wald. A Sequential Analysis. Wiley: New York 1947.